How does MRKC's PE Ratio compare to its peers?

MRKC is good value based on its Price-To-Earnings Ratio (22.6x) compared to the peer average (61.4x).

How does MRKC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

MRKC is expensive based on its Price-To-Earnings Ratio (22.6x) compared to the European Pharmaceuticals industry average (20.6x).

What is MRKC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate MRKC's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of MRKC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MRKC (€30.8) is trading below our estimate of [[fair value]] (€68.29)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Merck KGaA (BST:MRKC) - Stock Price, News & Analysis

MRKC Stock Overview

Operates as a science and technology company in Germany. More details

MRKC fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 54.9% below our estimate of its fair value

Earnings are forecast to grow 10.7% per year

Risk Analysis

Shares are highly illiquid

Merck KGaA Competitors

Dermapharm Holding

XTRA:DMP

€1.9b

PharmaSGP Holding

XTRA:PSG

€292.6m

Sartorius

XTRA:SRT3

€13.1b

GSK

LSE:GSK

UK£53.5b

Price History & Performance

Summary of all time highs, changes and price drops for Merck KGaA
Historical stock prices
Current Share Price	€30.80
52 Week High	€33.20
52 Week Low	€27.40
Beta	0.71
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-27.36%
5 Year Change	46.67%
Change since IPO	410.15%

Recent updates

Shareholder Returns

	MRKC	DE Pharmaceuticals	DE Market
7D	0%	-10.1%	-1.5%
1Y	n/a	-21.6%	7.9%

Return vs Industry: Insufficient data to determine how MRKC performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MRKC performed against the German Market.

Price Volatility

Is MRKC's price volatile compared to industry and market?
MRKC volatility
MRKC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: MRKC's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine MRKC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1668	62,255	Belen Garijo Lopez	www.merckgroup.com/en

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Merck KGaA Fundamentals Summary

How do Merck KGaA's earnings and revenue compare to its market cap?
MRKC fundamental statistics
Market cap	€60.87b
Earnings (TTM)	€2.70b
Revenue (TTM)	€20.96b

22.6x

P/E Ratio

2.9x

P/S Ratio

Is MRKC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRKC income statement (TTM)
Revenue	€20.96b
Cost of Revenue	€8.64b
Gross Profit	€12.33b
Other Expenses	€9.63b
Earnings	€2.70b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)	6.20
Gross Margin	58.80%
Net Profit Margin	12.86%
Debt/Equity Ratio	37.8%

How did MRKC perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

36%

Payout Ratio

MRKC Stock Overview

Rewards

Risk Analysis

Merck KGaA Competitors

XTRA:DMP

€1.9b

XTRA:PSG

€292.6m

XTRA:SRT3

€13.1b

LSE:GSK

UK£53.5b

Price History & Performance

Recent News & Updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Merck Launches New, High-Purity Synthetic Cholesterol Product

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2020 Results on Mar 04, 2021

MERCK Kommanditgesellschaft auf Aktien to Discontinue Bintrafusp Alfa Clinical Trial (INTR@PID Lung 037)

Merck KGaA, Darmstadt, Germany to Deploy Insilico Medicine's Chemistry42 AI Platform for Generative Chemistry

Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics

Iktos Announces Additional Collaboration with Merck KGaA, Darmstadt, Germany in AI for New Drug Design

Merck KGaA Announces Executive Changes

LycoRed Natural Products Industries Ltd. acquired Nutriblend Ltd. from Merck KGaA.

Rakuten Medical Enters into Partnership with Merck

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2021 Results on Aug 05, 2021

Shareholder Returns

Price Volatility

About the Company

Merck KGaA Fundamentals Summary

22.6x

2.9x

Earnings & Revenue

Dividends

1.6%

36%